Dupilumab, targeting IL‐4 and IL‐13 pathways, is approved for treating various T2IDs, including moderate to severe atopic dermatitis, severe bronchial asthma with type 2 reaction, severe chronic rhinosinusitis with nasal polyps, prurigo nodularis, eosinophilic esophagitis and recently as an add‐on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD) characterized by raised blood eosinophils. The gene discussed is IL13; the disease is chronic obstructive pulmonary disease.